Testosterone Supplement Investigation (AndroGel)

Goldenberg Schneider is currently investigating AndroGel and similar testosterone supplements due to emerging evidence that they substantially increase the risk of stroke, heart attack, and death in their users.  Two large, recent studies suggest that using testosterone supplements may double or even triple the risk of heart attack.  As the result of drug manufacturers’ widespread direct-to-consumer advertisements that paint testosterone supplements as fountain of youth – capable of treating such vague symptoms as lack of energy, weight gain, and decreased sex drive – treatments for low testosterone are now estimated to be a $2 billion-a-year industry.  The U.S. Food and Drug Administration (“FDA”) originally approved use of AndroGel to treat testosterone levels that are low due to a specific medical condition known as hypogonadism.  But with as many as 25% of all prescriptions for testosterone supplements now being written without first performing blood tests to check the patients’ testosterone levels and cardiovascular risks, the FDA has announced a new investigation into the safety of testosterone supplements.

If you or anyone you know suffered a stroke, heart attack or died while taking AndroGel or another testosterone supplement and would like additional information about your legal rights, we would be pleased to review the circumstances and discuss the matter with you.  You can contact us at 513.345.8291.

← Back To Investigations